Background-Little
T he Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation (COURAGE) Trial, in which patients with stable coronary artery disease (CAD) were randomly treated with either optimal medical treatment (OMT) or percutaneous coronary intervention (PCI) with OMT, reported that PCI with OMT as an initial management strategy did not reduce rates of mortality, myocardial infarction (MI), or other major cardiovascular events compared with an initial strategy of OMT alone. 1 There were small benefits of PCI compared with medical therapy in angina control that disappeared by 36 months. 2 The OMT was supported by training nurse-managers to counsel patients to help them achieve lifestyle and risk factor reduction goals, providing medications at no cost to patients, and following up with patients at 1,2, 4, and 6 months and every 6 months thereafter. The resulting adherence to lifestyle and medication prescription was quite high (eg, 96% adherence to antiplatelets, 85% to ␤-blockers, 93% to statin use). [3] [4] [5] [6] 
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However, little is known about how often patients with stable CAD undergo PCI in routine medical practice or how their outcomes compare with those of patients who do not undergo PCI. The purpose of this study is to compare outcomes for PCI with routine medical treatment (RMT) versus RMT in a setting with usual care, not as part of a clinical trial that focused on ensuring/improving adherence to medications or lifestyle changes.
Methods End Points
End points in the study were 4-year mortality, MI, readmission for MI, and subsequent revascularization.
Databases
The primary database used in the study was New York State's Cardiac Diagnostic Catheterization Database (CD2), a voluntary data system in New York maintained by the New York State Department of Health. For patients undergoing cardiac catheterization in New York, the database contains information on demographics, comorbidities, payer, angina type and class, stress test results, previous MI, previous revascularization procedures, ejection fraction, ongoing ischemia, vessels diseased, ejection fraction, congestive heart failure, diabetes mellitus, shock, hemodynamic instability, and area of viable myocardium at risk. Important variables that are also included are whether the patient's anatomy was suitable for PCI or for CABG surgery and whether the patient had a noncardiac comorbidity contraindicating PCI.
Completeness of data reporting is monitored by matching CD2 to the New York acute care hospital discharge database, the Statewide Planning and Research Cooperative System (SPARCS); the Department of Health's Ambulatory Surgery Database; and the New York PCI registry (Percutaneous Coronary Interventions Reporting System); and identifying cases reported with a diagnostic catheterization in those databases that were not reported to CD2. Hospitals are required to provide data for those missing cases. In addition, missing or invalid data elements are returned to hospitals for review and correction on an ongoing basis.
Matching CD2 with the PCI registry and SPARCS enabled us to identify those catheterization patients who underwent PCI within 30 days of the catheterization without having experienced an MI in the interim. The match between CD2 data and SPARCS was also done for 2 purposes other than ensuring completeness. First, for patients who did not undergo PCI within 30 days of catheterization, SPARCS was used to confirm that the patient identification was correct for linking with other databases. Second, SPARCS data were used to identify readmissions for MI, using acute MI (International Classification of Disease, ninth edition, clinical modification code 410.x1 as a principal diagnosis, with the fifth digit of 1 to ensure that it was the first episode of care for a newly diagnosed MI). The fourth database used in the study was the Social Security Administration Death Master File. Patient identifiers in CD2 were used to link the index catheterization to the Death Master File data to identify deaths after discharge for the purpose of identifying longer-term mortality.
Patients, Hospitals, and Outcomes
Patients in the study were New York State residents who underwent cardiac catheterization and were judged to have stable CAD. Entry criteria included being asymptomatic or having stable angina with Canadian Cardiovascular Society class I through III and at least 70% stenosis in a proximal epicardial coronary artery or its major branch. Exclusion criteria included left main coronary disease with Ն50% stenosis, life-threatening ventricular arrhythmia within a week before the procedure, concomitant valvular heart disease likely to require surgery, class IV angina, a negative or a high-risk stress test, cardiogenic shock, a recent (Ͻ21 days) acute MI, severe left ventricular dysfunction (ejection fraction Ͻ30% or ejection fraction Ͻ35% and proximal left anterior descending artery disease), revascularization within the previous 6 months, CABG surgery as the choice for revascularization, coronary anatomy not suitable for PCI (including chronic total occlusion), and a noncardiac comorbidity contraindicating PCI. The study was limited to New York State residents because the subsequent revascularization information was obtained from the PCI registry and the MI outcome was obtained from the SPARCS data.
Remaining patients were included in the study as PCI/RMT patients if they underwent PCI within a month of the index catheterization without having experienced an MI in the interim. Patients were included as RMT patients in the study if they were alive 30 days after the index catheterization without having undergone PCI or CABG surgery or suffered an MI and if they could be identified in SPARCS to ensure that they could be tracked in SPARCS and the Social Security Administration Death Master File (30 patients could not be tracked). A subsequent sensitivity analysis was conducted by defining PCI patients as the group of patients undergoing PCI in the index admission and RMT patients as the group who did not undergo PCI in the index admission. A total of 20 hospitals were represented in the database, and 18 of these hospitals were represented after propensity matching (see below). All were hospitals with Certificate of Need approval to perform cardiac catheterization, and 8 were certified to perform PCI. Outcomes of the study include 4-year mortality, mortality/MI (mortality and/or MI), MI, and subsequent revascularization.
Statistical Analyses
Because patients were not randomized to PCI/RMT versus RMT, we identified patient characteristics that were potentially related to the type of treatment selected as well as being potential predictors of adverse outcomes. We first compared the prevalences of these risk factors among PCI and RMT patients using 2 tests. Because many of the prevalences proved to be significantly different, propensity score matching was used to identify a set of matched PCI/RMT and RMT pairs so that confounding could be reduced. Patients were matched on the basis of time interval of catheterization, age, Canadian Cardiovascular Society angina class, ejection fraction, area of viable myocardium at risk, renal failure (on dialysis or creatinine Ͼ2.5 mg/dL), extent of cardiovascular disease, primary payer, demographics, body mass index, median per capita income of the patient's ZIP code, congestive heart failure, left ventricular function, previous MI, previous PCI Ͼ6 months previously (more recent PCIs were excluded from the study), CABG surgery Ͼ6 months previously, and a few comorbidities (cerebrovascular disease, peripheral vascular disease, diabetes mellitus). The propensity score was derived by using a logistic regression model to predict the probability of undergoing PCI with RMT rather than RMT alone for each patient as a function of the risk factors just noted.
A global optimization matching algorithm (one that picks pairs of RMT and PCI/RMT patients so that the sum of distances between the propensity scores of the paired patients is minimized) was used, with matching allowed only if the difference in the logits of the matched propensity scores was Ͻ0.6 times the SDs of the scores. [7] [8] [9] [10] Matching was on a 1:1 basis; each matched pair was unique; and data for unmatched patients were not used in subsequent analyses. The balance between patient characteristics in the paired groups was tested by computing the standardized differences between the 2 groups (RMT and PCI/ RMT) for each of the matched characteristics. A difference Ͻ0.1 (10%) was regarded as acceptable. 11 The propensity-matched pairs were then used to analyze differences in outcomes between the 2 groups. Methods were used to compare RMT and PCI/RMT for a 4-year follow-up period for each of the outcomes by use of Kaplan Meier survival curves with Klein and Moeschberger tests in view of the fact that the samples were matched. 12 After the proportional hazards assumption was confirmed to be valid, Cox proportional hazards models were fit to the matched pairs to adjust for any remaining differences in patient characteristics, and adjusted RMT/PCI with RMT hazard ratios were obtained for each of the adverse outcomes.
The impact of treatment type on mortality/MI for a few preselected risk factor subgroups of interest (age, extent of CAD, angina class, and area of viable myocardium at risk) was also tested to determine whether the differential in outcomes for PCI and RMT differed according to these preselected risk factors and if there was Analyses were performed according to the intention to treat, with medical patients undergoing PCI Ͼ30 days after the index catheterization regarded as medical patients. All tests were 2-sided and conducted at the 0.05 level, and all analyses were conducted in SAS 9.1 (SAS Institute, Inc, Cary, NC).
Results

Characteristics of Patients and Providers Before Propensity Score Matching
The median follow-up time was 2.87 years (2.94 years for PCI/RMT patients, 2.81 years for RMT patients). Of the 9586 total patients, 8486 (88.5%) underwent PCI and 196 (2.0%) underwent CABG surgery. The PCI percentage did not change substantially before and after the COURAGE trial findings (88.4% before 2008, 88.7% after 2008). As indicated in Table 1 , PCI/RMT patients were younger, were more likely to be white, and were more likely to have private health insurance, a positive stress test, a medium or large area of viable myocardium at risk, proximal left anterior descending artery disease and 3-vessel disease, class III angina, and a higher ejection fraction. PCI/RMT patients were less likely to have peripheral vascular disease or previous cardiac surgery. For patients undergoing PCI, 91% of the patients had 1 vessel attempted and 9% had 2 vessels attempted. In addition, 72% had 1 lesion attempted and 23% had 2 lesions attempted. A total of 71% had 1 stent placed and 20% had 2 stents placed. Most patients had drug-eluting stents (71%) or bare metal stents (24%); only 5% of patients did not receive a stent.
After Propensity Score Matching
The process of propensity score matching resulted in being able to match 933 (84.8%) of the medical therapy patients to a very similar PCT/RMT patient. There were no significant differences between the 2 groups in any of the characteristics examined. As Table 2 demonstrates, the characteristics of the matched pairs were extremely similar, with only one of the standardized differences exceeding 10%. After matching, a total of 18 of the 20 hospitals in the database were included. Matched patients underwent PCIs in a total of 27 hospitals by 120 cardiologists. The previous data include planned staged PCI procedures in the PCI/RMT group. On the basis of staging data available only in the last 2 years of the study that were extrapolated to all years, the subsequent revascularization rate for unstaged PCI/RMT patients is estimated to be 19.7%.
Adverse Outcome Rates
Adjusted hazard ratios representing the relative outcomes across the entire follow-up period were also significant in favor of PCI with RMT versus RMT alone, with ratios ranging from 1.39 to 1.56. For the subset of 789 matched pairs in whom PCI patients were defined as patients undergoing PCI in the index admission and RMT patients were patients who did not undergo PCI in the index admission or within 30 days, the RMT versus PCI with RMT outcomes were as follows: 20.5% versus 15.4% (Pϭ0.01; adjusted hazard ratioϭ1.47; 95% confidence interval, 1.10 -1.95) for mortality/MI; 13.5% versus 10.1% (Pϭ0.01; adjusted hazard ratioϭ1.37; 95% confidence interval, 1.01-1.85) for mortality; 10.9% versus 7.1% (Pϭ0.01; adjusted hazard ratioϭ1.73; 95% confidence interval, 1.15- Table 4 shows that across all subgroups of patients except age Ͻ65 years, the adjusted hazard ratios were Ͼ1, indicating higher mortality for RMT. Only 1 interaction term (the interaction between age and treatment type) was significant, indicating that the impact of treatment type on mortality might depend on age, with the benefit of PCI relative to RMT being significantly higher for patients Ն65 years of age than for patients Ͻ65 years of age.
Adverse Outcome Rates for Patient Subgroups
Discussion
Although the COURAGE trial compared outcomes for patients with stable CAD undergoing PCI and medical therapy, it is not well known how often these patients undergo PCI in routine medical practice or what the outcomes are with and without PCI. Our study found that in a population-based study in New York of patients with stable CAD undergoing cardiac catheterization, nearly 90% of these patients underwent PCI. This percentage did not change even in 2008, well after the COURAGE results had been published. In addition, the propensity-matched patients who underwent PCI experienced significantly lower mortality, mortality/ MI, and revascularization rates than the patients who did not undergo PCI. Our outcomes rates for mortality/MI at 4 years were 16.5% for PCI/RMT and 21.2% for RMT compared with 19.0% and 18.5% for the COURAGE trial at 4.6 years. Our mortality rates at 4 years were 10.2% for PCI/RMT and 14.5% for RMT compared with 7.6% for PCI/OMT and 8.3% for OMT in COURAGE at 4.6 years. Although our RMT and PCI/ RMT rates both were higher than the COURAGE rates, we hypothesize that our PCI/RMT rates were more similar to the COURAGE rates because drug-eluting stents were used in 74% of the patients in our study compared with all bare metal stents in COURAGE, and drug-eluting stents have been shown to be associated with lower mortality rates than bare metal stents in observational studies, although not in randomized controlled trials. 13 Two possible reasons why the RMT outcome rates in our study were higher than in COURAGE are that our RMT population was significantly less selected (and therefore at a higher risk) and that patients had RMT instead of OMT. A few factors may contribute to our findings. First, the observational nature of this study means that it is subject to selection bias, whereby the results are driven by differences among the patient populations rather than relative effectiveness of the treatments. Indeed, RMT patients appeared to be at higher risk than their PCI/RMT counterparts in the full study sample. We propensity matched patients based on numerous risk factors related to demographics, socioeconomics, payer, extent of CAD, stress test results, area of viable myocardium at risk, ventricular function, angina class, and comorbidities in an attempt to minimize this bias. In addition, all patients in the study were candidates for PCI. As a result, the subset of propensity-matched patients used in the study looked extremely similar with respect to those risk factors. Furthermore, the design of the study was such that any patients who died or experienced an MI within 30 days of the index catheterization without undergoing PCI were removed from the study rather than being placed in the RMT group in case they might have been assigned to PCI within 30 days. This was done despite the fact that 95% of the patients undergoing PCI received it within 1 week and 98% received it within 2 weeks. Nevertheless, unmeasured factors such as lesion characteristics, bleeding risk, and some noncardiac comorbidities (eg, cancer) and the possible differential use of appropriate medications could have biased the outcomes of the study in favor of PCI/RMT. The risk of unmeasured confounders is also enhanced by virtue of the large proportion of patients in the study who underwent PCI. We had no information on why the decision was made to refer each patient for PCI, and once the coronary anatomy is known, there is a bias toward revascularization.
However, it is also true that patients in the COURAGE trial constituted a highly select population willing to be randomized after angiography. Certainly, many high-risk patients were excluded, which contributed to the lower mortality rate in COURAGE. Thus, the fact that our study represents a real-world experience at least partially offsets the limitation of the lack of natural randomization.
Another limitation is that, because we used SPARCS to track readmissions for MI and New York State registries to track subsequent CABG and target vessel PCI, we restricted the study to New York State patients. However, if patients moved outside the state after discharge and were admitted for MI or underwent revascularization out of state, these events would have been missed by our study. Moreover, the study would miss New York State patients who underwent a repeat revascularization out of state. We do not believe there is a good reason why there would be a bias in favor of PCI/RMT with respect to missed patients, and an earlier study demonstrated that there was not a bias in this regard. 14 The extent to which lesser use of OMT in our study compared with COURAGE explains some of the differences in the study results deserves further investigation. The nature of the medical therapy provided to the RMT patients in our study is completely unknown, and undoubtedly many RMT patients received nonoptimal treatment. Several studies have shown that medication adherence is generally poor, [15] [16] [17] [18] [19] [20] [21] and several other studies have shown that adherence strongly affects outcomes. 17, 19, [22] [23] [24] [25] [26] In addition, studies from the COURAGE group demonstrate that adherence to both suggested lifestyle changes and medications was excellent in their trial. 2, 3 The combination of these facts suggests that although OMT is as effective as PCI/OMT for patients with stable CAD in a tightly controlled trial with excellent adherence, different results might occur in real-world situations. As noted by Ho et al, 20 there are multifactorial reasons for poor adherence, including challenges presented by the health system (eg, patient-provider relationship, access problems), patient condition (eg, depression, cognitive impairment, psychological problems), therapy (eg, side effects, complex regimen), and socioeconomic problems (eg, low literacy, no or inadequate insurance).
Thus, the key findings of the study are that, with standard medical care, the vast majority of catheterization patients in New York between 2003 and 2008 were treated with PCI rather than by medical therapy alone and that patients with stable CAD treated with PCI had improved outcomes compared with patients who did not undergo PCI. The reasons for these findings need to be better understood, including the role of the inability to achieve OMT in routine medical practice. A randomized controlled trial in which patients are randomized to PCI and MT without efforts to guarantee OMT would serve as a definitive test of how patients in routine medical practice fare with each of the interventions. 
